Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02605122 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia
A Phase 2 study, sponsored by Melinta Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
NCT02605122 is a Phase 2 study that was terminated before completion, run by Melinta Therapeutics. The registered enrollment target is 97 participants.
The verdict
NCT02605122, a Phase 2 study, was terminated before completion, sponsored by Melinta Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
Study Summary
This is a phase 2/3, randomized, open-label, active control, multi-center study to assess the safety and efficacy of solithromycin in children and adolescents with community-acquired bacterial pneumonia (CABP).
Interventions
- DRUG Standard of Care
- DRUG Solithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2016-04 |
| Est. Completion | 2018-03-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02605122
The ClinicalTrials.gov registry entry for NCT02605122 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT02605122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02605122 about?
NCT02605122 is a clinical study titled "Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia". This is a phase 2/3, randomized, open-label, active control, multi-center study to assess the safety and efficacy of solithromycin in children and adolescents with community-acquired bacterial pneumonia (CABP).
What is the current status of trial NCT02605122?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2016-04. Estimated completion is 2018-03-21.
What interventions are being tested in trial NCT02605122?
The interventions under investigation include: Standard of Care (DRUG), Solithromycin (DRUG).
Who is sponsoring clinical trial NCT02605122?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.